Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. ABBV
7. DFTX
8. USO
9. APGE
10. HOOD

Go back to Impel NeuroPharma Announces U.S. FDA Approval of TRUDHESA™ (Dihydroergotamine Mesylate) Nasal Spray for the Acute Treatment of Migraine
(NASDAQ: IMPL) Delayed: 0.24 --0 (-0%)
Previous Close $0.24    52 Week High $ 
Open $0.05    52 Week Low $ 
Day High $0.24    P/E N/A 
Day Low $0.24    EPS $ 
Volume 15,000